.jpg)
Barclays analyst Jack Meehan maintained a Buy rating on Hologic (NASDAQ: HOLX) today and set a price target of $50. The company’s shares opened today at $36.10, close to its 52-week low of $35.10.
According to TipRanks.com, Meehan is a 4-star analyst with an average return of 9.1% and a 61.6% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Genomic Health, Quidel Corp, and Waters Corp.
Currently, the analyst consensus on Hologic is Moderate Buy and the average price target is $44.36, representing a 22.9% upside.
In a report released today, Needham also reiterated a Buy rating on the stock with a $43 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $46.80 and a one-year low of $35.10. Currently, Hologic has an average volume of 2.47M.
Based on the recent corporate insider activity of 71 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of HOLX in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following business segments: Breast Health, Diagnostics, Medical Aesthetics, GYN Surgical, and Skeletal Health.
